

## Desidustat: Adis Evaluation

### Key Points

- An orally bioavailable, small molecule, HIF-PH inhibitor is being developed by Zydus Cadila for the treatment of anaemia associated with CKD, COVID-2019 infections and chemotherapy induced anaemia
- Received its first approval on 7 March 2022 in India
- Approved for the treatment of anaemia in adults with CKD who are either on dialysis or not on dialysis

### Summary

Desidustat (Oxemia™) is an orally bioavailable, small molecule, hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor developed by Zydus Cadila for the treatment of anaemia associated with chronic kidney disease (CKD), COVID-2019 infections and chemotherapy induced anaemia.

Desidustat inhibits prolyl hydroxylase domain enzymes, resulting in the stabilisation of hypoxia-inducible factor which stimulates erythropoietin production and erythropoiesis.

In March 2022, desidustat received its first approval in India for the treatment of anaemia in adults with CKD who are either on dialysis or not on dialysis. Desidustat is in clinical development in China for the treatment of anaemia in patients with CKD, in Mexico for the management of COVID-2019 infections and in the USA for the treatment of chemotherapy induced anaemia.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.